Video

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, professor, Medicine and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the importance of molecular profiling when utilizing precision medicine.

Irrespective of tumor type, molecular profiling is an important step to optimizing treatment for the majority of patients with cancer, particularly those with metastatic disease, Marshall says. Moreover, broad molecular profiling is becoming increasingly important because although many identifiable alterations are rare, they cannot be identified unless testing is completed. Additionally, it is critical to keep track of what was tested for in case the information needs to be referenced, Marshall adds.

Although this technology is evolving, a patient’s tumor may also be evolving, which signifies the importance of repeat testing with liquid or tissue biopsy, Marshall continues. Although not all cancer types require extensive repeat testing, some do, Marshall adds. Therefore, implementing basic principles of molecular testing will ultimately improve patient care and patient outcomes, Marshall concludes.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center